Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company focused on precision cancer medicines, and its news flow reflects ongoing progress in oncology research, clinical development, and corporate strategy. The company describes itself as dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer, using the genetic principle of synthetic lethality to identify and pursue critical targets in tumors.
News about Tango Therapeutics often highlights updates from its clinical pipeline, including vopimetostat (TNG462), an oral MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers, TNG456, a brain-penetrant PRMT5 inhibitor in development for glioblastoma and malignant glioma, and TNG260, a first-in-class CoREST complex inhibitor being evaluated with pembrolizumab in STK11-mutant solid tumors. Press releases have detailed Phase 1/2 clinical data, trial enrollment status, and regulatory designations such as Orphan Drug Designation for TNG456.
The company also issues news on corporate and financial developments, including leadership transitions, board appointments, equity financings, and at-the-market offering agreements documented in SEC filings. Announcements about participation in major healthcare investment conferences and scientific meetings, such as the J.P. Morgan Healthcare Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting, provide additional context on how Tango Therapeutics communicates its strategy and data to investors and the scientific community.
Investors and followers of TNGX can use this news page to review company-issued press releases on clinical results, pipeline milestones, financing transactions, and governance changes, offering a consolidated view of how Tango Therapeutics is advancing its precision oncology programs based on synthetic lethality and targeted cancer biology.
Tango Therapeutics (NASDAQ: TNGX) announced the acceptance of two oral and two poster presentations at the AACR 2023 Annual Meeting from April 14-19 in Orlando, Florida. The oral presentations include TNG908, a promising PRMT5 inhibitor showing three-fold increased median survival in glioblastoma models, and TNG260, aimed at STK11-mutant cancers. The poster presentations feature TNG348, targeting BRCA1/2 mutations, and TNG462, another PRMT5 inhibitor for MTAP-deleted tumors. These findings highlight Tango's innovative approach in precision oncology and the potential for advancements in cancer treatment.
Tango Therapeutics (NASDAQ: TNGX) announced on March 10, 2023, that it is monitoring the situation involving Silicon Valley Bank (SVB) and expects no impact on its financial guidance. The company has sufficient cash, equivalents, and marketable securities to support operations through 2025.
Tango Therapeutics focuses on developing precision cancer medicines based on synthetic lethality. The company is dedicated to identifying new drug targets and advancing therapies that effectively address critical cancer mechanisms.
Tango Therapeutics (NASDAQ: TNGX) announced the grant of non-qualified stock options and restricted stock units (RSUs) totaling 637,000 shares and 106,250 RSUs, respectively, to two new employees as part of its 2023 Inducement Plan. This includes 487,500 stock options and 81,250 RSUs awarded to Adam Crystal, M.D., Ph.D., following his appointment as President of Research and Development. The options have an exercise price of $5.20 per share, aligning with the stock's closing price on the grant date, March 1, 2023. The vesting schedules for both options and RSUs are contingent upon continued employment.
Tango Therapeutics (NASDAQ: TNGX), a biotechnology company focused on advanced cancer treatments, announced key investor conference appearances in March 2023. CEO Barbara Weber will participate in the Cowen 43rd Annual Health Care Conference on March 8 at 11:10 AM ET in Boston, and the Barclays Global Healthcare Conference on March 14 at 3:35 PM ET in Miami. Live webcasts of these presentations will be accessible on their website, with replays available for 90 days post-event. Tango Therapeutics aims to leverage synthetic lethality to develop innovative cancer therapies targeting tumor suppressor gene loss.
Tango Therapeutics, a clinical-stage biotechnology firm (NASDAQ: TNGX), has appointed Adam Crystal, M.D., Ph.D. as President of Research and Development. Dr. Crystal will lead preclinical research, drug discovery, and clinical development, working with existing leaders in the company. Tango is currently enrolling patients in a crucial clinical trial and plans to introduce three more programs in the next year. Dr. Crystal's expertise in precision oncology is expected to enhance the advancement of Tango's pipeline, which focuses on synthetic lethal targeting in cancer treatment.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicine, is set to participate in key investor conferences this February. The first event is the Guggenheim Healthcare Talks | 2023 Oncology Conference on February 9, 2023, at 1:00 PM ET in New York. The second is the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET, conducted virtually. Live webcasts will be available on the Company's website, with replays archived post-presentation. Tango is committed to advancing cancer treatment through innovative drug targets and leveraging synthetic lethality principles.
Tango Therapeutics (NASDAQ: TNGX) recently announced significant developments in its clinical pipeline. The U.S. FDA has granted Orphan Drug Designation to TNG908 for treating malignant glioma, enhancing its market exclusivity and providing potential financial incentives. Additionally, the FDA cleared an Investigational New Drug (IND) application for TNG462, a next-generation inhibitor targeting MTAP-deleted cancers, with a clinical trial expected to start in mid-2023. These advancements may broaden the company's strategic options and opportunity to address unmet medical needs in oncology.
Tango Therapeutics (NASDAQ: TNGX) announced the approval of a Clinical Trial Application for TNG908, a PRMT5 inhibitor, by France's ANSM. The company introduced TNG260, targeting STK11-mutant cancers, and TNG348 as a USP1 inhibitor for BRCA1/2-mutant cancers. Aaron Weitzman, M.D., was appointed Chief Medical Officer. Financially, Tango reported Q3 2022 results: collaboration revenue of $6.9 million, a net loss of $29.1 million, and $393.3 million in cash, expected to fund operations into 2025, despite increased R&D and G&A expenses.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company, announced that its CEO, Barbara Weber, will participate in two investor conferences this November. The first event is the H.C. Wainwright 3rd Annual Precision Oncology Conference on November 14 at 11:00 AM ET, followed by the Jefferies London Healthcare Conference on November 15 at 10:20 AM GMT. Both presentations will be available via live webcast on the company’s website, with replays accessible for 90 days.
Tango Therapeutics (NASDAQ: TNGX) announced the selection of three abstracts for poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, scheduled from October 26-28, 2022. The posters will cover the characterization and potential of TNG908 and TNG462, both designed to target MTAP-deleted cancers. Notably, TNG908 is highlighted as a brain-penetrant inhibitor, while TNG462 aims to be a best-in-class option. These presentations showcase Tango's focus on precision cancer therapies.